Lee Goldstein, MD
Vascular Surgery · Stratford, CTNPI 1164579181
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $174,805 of the $271,891 with a category attached, or 64.3%. 35 manufacturers reported payments, led by Smith+Nephew at 47.4% of the total. Reporting peaked in 2024 at $87,028 and has fallen 59.3% since, to $35,431 in 2025. Among vascular surgery clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 477 payments — averaging $570.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$129K
- Johnson & Johnson$54K
- Pfizer$45K
- Lifenet Health$18K
- Bioventus LLC$11K
- E.r. Squibb & Sons, L.L.C.$6K
- plus $8K from 29 others
Across 6 payments — averaging $2348.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$12K
- W. L. Gore & Associates, Inc.$2K
What the payments were for
- Consulting fees$44,73816%
- Speaking & faculty fees$174,80564%
- Travel & lodging$37,21614%
- Food & beverage$15,1326%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 157 | $128,895 |
| Johnson & Johnson | 65 | $54,443 |
| Pfizer | 64 | $45,151 |
| Lifenet Health | 24 | $17,564 |
| Bioventus LLC | 11 | $11,440 |
| E.r. Squibb & Sons, L.L.C. | 34 | $5,988 |
| Lemaitre Vascular, Inc. | 3 | $2,974 |
| Silk Road Medical, Inc. | 9 | $1,068 |
| Bard Peripheral Vascular, Inc. | 14 | $971 |
| Kerecis Limited | 7 | $673 |
| Organogenesis Inc. | 12 | $345 |
| Davol Inc. | 3 | $311 |
| Medtronic(2 entities) | 13 | $280 |
| Inari Medical, Inc. | 6 | $266 |
| Next Science LLC | 3 | $229 |
| Integra Lifesciences Corporation | 3 | $174 |
| Hydrofera LLC | 5 | $153 |
| Boston Scientific | 8 | $142 |
| Cook Medical LLC | 10 | $141 |
| Shockwave Medical, Inc | 2 | $117 |
| Livanova USA, Inc. | 2 | $76 |
| KCI USA, Inc. | 3 | $67 |
| Solventum Corporation | 2 | $58 |
| Tactile Systems Technology Inc | 3 | $49 |
| Aroa Biosurgery Incorporated | 2 | $48 |
| Angiodynamics, Inc. | 2 | $42 |
| Endologix LLC | 1 | $42 |
| Molnlycke Health Care US, LLC | 1 | $33 |
| Cardiovascular Systems Inc. | 2 | $30 |
| Urgo Medical North America, LLC | 1 | $27 |
| Reprise Biomedical, Inc. | 1 | $26 |
| Mimedx Group, Inc. | 1 | $22 |
| Convatec Inc. | 1 | $17 |
| Biocompatibles, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Grafix$79,719
- GRAFIX PL$70,843
- Stravix$57,966
- Oasis$54,048
- XARELTO$53,534
- Grafix XC$50,535
- ELIQUIS$49,864
- OASIS MICRO$28,754
- NA$22,109
- TheraGenesis Wound Matrix$17,169
- COLLAGENASE SANTYL$11,480
- STRAVIX MESH$8,927
- Versajet$8,243
- PICO$8,039
- RENASYS TOUCH$6,830
- STRAVIX PL$6,760
- Allevyn Gentle Border 10 x 10cm Ctn 10$6,097
- VALVULOTOM$2,921
- ACTICOAT 4" X 4"$1,497
- Kerecis Omega3 Marigen$1,327
How this compares
$271,891 in reported general payments places this provider in the 95th percentile of 82 vascular surgery providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 16 | $31,837 |
| Metronidazole | 41 | $1,383 |
| Doxycycline Monohydrate | 63 | $1,025 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 15 | $745 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 17 | $200 |
| Levofloxacin | 45 | $125 |
| Oxycodone Hcl | 15 | $38 |
| Tramadol Hcl | 19 | $38 |
| Ibuprofen | 12 | $28 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $128,895 | $31,83716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 82 vascular surgery providers in Connecticut.
Other vascular surgery in Stratford
- Bruce SwearingenStratford$11K
- Joshua HarrisStratford$7K
- Marsel HuribalStratford$7K
- Michael SergiStratford$5K
- Uwe FischerNew London$941K
- Paul GagneDarien$766K
- Naiem NassiriNew Haven$348K
- Mohiuddin CheemaHartford$228K
- Bauer SumpioNew Haven$205K
- Javairiah FatimaDanbury$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.